OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

ASCO 2024

Genitourinary Cancer

Real-world study: Apalutamide achieved improved deep, early PSA response versus enzalutamide in patients with de novo mHSPC

ASCO 2024

Genitourinary Cancer

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

EHA 2024

Multiple Myeloma (MM)

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

ASCO 2024

Genitourinary Cancer

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

ASCO 2024

Multiple Myeloma (MM)

DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

ESMO 2024

Genitourinary Cancer

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

APCCC 2024

Genitourinary Cancer

Related content

Real-world study: Apalutamide achieved improved deep, early PSA response versus enzalutamide in patients with de novo mHSPC

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Ideal sequence after ADT alone or ADT plus ARPI for mHSPC